摘要
目的研究99mTc-ASON-EGF放射性药物在荷乳腺癌BALB/c裸鼠体内的分布及反义显像。方法制备99mTc-ASON-EGF,用SKBR-3细胞构建荷乳腺癌裸鼠模型;随后用放射性计数法测定其在荷乳腺癌BALB/c裸鼠体内的生物分布;最后在荷乳腺癌裸鼠模型中进行反义显像。结果99mTc-ASON-EGF经鼠尾静脉注射后0.5、1、2、4h,在乳腺癌组织中的%ID/g值分别是4.17、11.32、18.36、7.86;其中,2h最高,为18.36;同样,经鼠尾静脉注射0.5、1、2、4h后进行反义显像,2h效果最好。结论99mTc-ASON-EGF在体内具有良好的稳定性,在乳腺癌组织高浓聚,且在靶部位显像效果好,可望用于乳腺癌的显像诊断和治疗。
Objective To study the distribution and antisense imaging of ^99mTc-ASON-EGF radiopharmaceuticals in breast cancer-bearing BALB/c nude mouse models. Methods ^99mTc-ASON-EGF was prepared according to previous methods and the breast cancer-bearing nude mouse models were established by SKBR-3 cells. Subsequently, its biodistribution was measured by radioactivity counts per minute （cpm）. Finally, its antisense imaging was accomplished in the breast cancer-bearing nude mouse models. Resuits After being injected through mouse trail vein, the %ID/g value of ^99mTc-ASON-EGF, at 0.5h, lh, 2h and 4h, was 4.17, 11.32, 18.36 and 7.86 respectively. Its biggest value was 18.36 at 2h. After being injected for 2h, ^99mTc-ASON-EGF formed the best and clearest antisense imaging in model. Conclusion ^99mTc-ASON-EGF has desirable stability in vivo, higher uptake and better imaging in breast cancer, so it may be a new sensitive tool for diagnostic imaging and therapy for breast cancer in the future.
出处
《重庆医学》
CAS
CSCD
2006年第19期1770-1772,共3页
Chongqing medicine
